In melanoma patients, tumor peptide antigen vaccination combined with low-dose cyclophosphamide and low-dose IL-2 evoked Th1-like Treg accumulation, in line with a less tolerogenic microenvironment and with enhanced IL-12 availability (158). This evidence concerns the gene IL2 and melanoma.